The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
Open accessAbstract
Aberrant activation of intracellular signalling pathways confers malignant properties on cancer cells. Targeting intracellular signalling pathways has been a productive strategy for drug development, with several drugs acting on signalling pathways already in use and more continually being developed. The JAK/STAT signalling pathway provides an example of this paradigm in haematological malignancies, with the identification of JAK2 mutations in myeloproliferative neoplasms leading to the development of specific clinically effective JAK2 inhibitors, such as ruxolitinib. It is now clear that many solid tumours also show activation of JAK/STAT signalling. In this review, we focus on the role of JAK/STAT signalling in solid tumours, examining the molecular mechanisms that cause inappropriate pathway activation and their cellular consequences. We also discuss the degree to which activated JAK/STAT signalling contributes to oncogenesis. Studies showing the effect of activation of JAK/STAT signalling upon prognosis in several tumour types are summarised. Finally, we discuss the prospects for treating solid tumours using strategies targeting JAK/STAT signalling, including what can be learned from haematological malignancies and the extent to which results in solid tumours might be expected to differ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1312542 · Cited by 1,756
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., Niu, G., Kay, H., Mulé, J., Kerr, W. G., et al. (2005) · Nature Medicine · doi:10.1038/nm1325 · Cited by 1,031
Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia
Koskela, H. L. M., Eldfors, S., Ellonen, P., van Adrichem, A. J., Kuusanmäki, H., Andersson, E. I., Lagström, S., Clemente, M. J., Olson, T., Jalkanen, S. E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114885 · Cited by 777
Zorn, E., Nelson, E. A., Mohseni, M., Porcheray, F., Kim, H., Litsa, D., Bellucci, R., Raderschall, E., Canning, C., Soiffer, R. J., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004747 · Cited by 740
Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation
Gough, D. J., Corlett, A., Schlessinger, K., Wegrzyn, J., Larner, A. C., & Levy, D. E. (2009) · Science · doi:10.1126/science.1171721 · Cited by 716
Tofacitinib versus methotrexate in rheumatoid arthritis
Lee, E. B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J. D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G. V., Zang, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310476 · Cited by 711
JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
Dawson, M. A., Bannister, A. J., Göttgens, B., Foster, S. D., Bartke, T., Green, A. R., & Kouzarides, T. (2009) · Nature · doi:10.1038/nature08448 · Cited by 622
JAK/STAT signaling in hematological malignancies
Vainchenker, W., & Constantinescu, S. N. (2013) · Oncogene · doi:10.1038/onc.2012.347 · Cited by 528
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
Kan, Z., Zheng, H., Liu, X., Li, S., Barber, T. D., Gong, Z., Gao, H., Hao, K., Willard, M. D., Xu, J., et al. (2013) · Genome Research · doi:10.1101/gr.154492.113 · Cited by 523
Hughes, T. P., Hochhaus, A., Branford, S., Müller, M. C., Kaeda, J. S., Foroni, L., Druker, B. J., Guilhot, F., Larson, R. A., O'Brien, S. G., et al. (2010) · Blood · doi:10.1182/blood-2010-03-273979 · Cited by 489
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., Chang, A., Kraker, A., Jove, R., & Yu, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205859 · Cited by 432
Cervantes, F., Vannucchi, A. M., Kiladjian, J.-J., Al-Ali, H. K., Sirulnik, A., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R. S., Passamonti, F., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485888 · Cited by 426
Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor
Brooks, A. J., Dai, W., O’Mara, M. L., Abankwa, D., Chhabra, Y., Pelekanos, R. A., Gardon, O., Tunny, K. A., Blucher, K. M., Morton, C. J., et al. (2014) · Science · doi:10.1126/science.1249783 · Cited by 418
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer
He, B., You, L., Uematsu, K., Zang, K., Xu, Z., Lee, A. Y., Costello, J. F., McCormick, F., & Jablons, D. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2232790100 · Cited by 380
ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases
Olayioye, M. A., Beuvink, I., Horsch, K., Daly, J. M., & Hynes, N. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17209 · Cited by 367
Ras-Independent Growth Factor Signaling by Transcription Factor Tyrosine Phosphorylation
Silvennoinen, O., Schindler, C., Schlessinger, J., & Levy, D. E. (1993) · Science · doi:10.1126/science.8378775 · Cited by 338
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
Flex, E., Petrangeli, V., Stella, L., Chiaretti, S., Hornakova, T., Knoops, L., Ariola, C., Fodale, V., Clappier, E., Paoloni, F., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072182 · Cited by 334
Sen, M., Thomas, S. M., Kim, S., Yeh, J. I., Ferris, R. L., Johnson, J. T., Duvvuri, U., Lee, J., Sahu, N., Joyce, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0191 · Cited by 313
Self-citation(2003) · PubMed · Cited by 272
A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction
Demaria, M., Giorgi, C., Lebiedzinska, M., Esposito, G., D'Angeli, L., Bartoli, A., Gough, D. J., Turkson, J., Levy, D. E., Watson, C. J., et al. (2010) · Aging · doi:10.18632/aging.100232 · Cited by 250
Activation of STAT3 is a marker of poor prognosis in human colorectal cancer
Kusaba, T., Nakayama, T., Yamazumi, K., Yakata, Y., Yoshizaki, A., Inoue, K., Nagayasu, T., & Sekine, I. (2006) · Oncology Reports · doi:10.3892/or.15.6.1445 · Cited by 238
STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells
Pawlus, M. R., Wang, L., & Hu, C.-J. (2014) · Oncogene · doi:10.1038/onc.2013.115 · Cited by 226
Brantley, E. C., Nabors, L. B., Gillespie, G. Y., Choi, Y.-H., Palmer, C. A., Harrison, K., Roarty, K., & Benveniste, E. N. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0618 · Cited by 191
Horiguchi, A., Oya, M., Shimada, T., Uchida, A., Marumo, K., & Murai, M. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64741-6 · Cited by 165
Gallipoli, P., Cook, A., Rhodes, S., Hopcroft, L., Wheadon, H., Whetton, A. D., Jørgensen, H. G., Bhatia, R., & Holyoake, T. L. (2014) · Blood · doi:10.1182/blood-2013-12-545640 · Cited by 158
Gough, D. J., Koetz, L., & Levy, D. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083395 · Cited by 138
Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas
Liu, F., Cao, J., Wu, J., Sullivan, K., Shen, J. L., Ryu, B., Xu, Z., Wei, W., & Cui, R. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.32 · Cited by 135
Janus kinase deregulation in leukemia and lymphoma
Chen, E., Staudt, L. M., & Green, A. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.017 · Cited by 123
STAT3 mediates TGF-β1-induced TWIST1 expression and prostate cancer invasion
Cho, K. H., Jeong, K. J., Shin, S. C., Kang, J., Park, C. G., & Lee, H. Y. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.024 · Cited by 117
Xu, Y., & Lü, S. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.11.012 · Cited by 115
Bendell, J. C., Hong, D. S., Burris, H. A., Naing, A., Jones, S. F., Falchook, G., Bricmont, P., Elekes, A., Rock, E. P., & Kurzrock, R. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2480-2 · Cited by 115
AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors
Plimack, E. R., LoRusso, P. M., Mccoon, P. E., Tang, W., Krebs, A. D., Curt, G. A., & Eckhardt, S. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0198 · Cited by 115
Takemoto, S., Ushijima, K., Kawano, K., Yamaguchi, T., Terada, A., Fujiyoshi, N., Nishio, S., Tsuda, N., Ijichi, M., Kakuma, T., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605212 · Cited by 105
Prognostic significance of nuclear pSTAT3 in oral cancer
Macha, M. A., Matta, A., Kaur, J., Chauhan, S. S., Thakar, A., Shukla, N. K., Gupta, S. D., & Ralhan, R. (2010) · Head & Neck · doi:10.1002/hed.21468 · Cited by 105
Peck, A. R., Witkiewicz, A. K., Liu, C., Stringer, G. A., Klimowicz, A. C., Pequignot, E. C., Freydin, B., Tran, T. H., Yang, N., Rosenberg, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3552 · Cited by 103
The targeting of immunosuppressive mechanisms in hematological malignancies
Andersen, M. H. (2014) · Leukemia · doi:10.1038/leu.2014.108 · Cited by 97
HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer
Rath, K. S., Naidu, S. K., Lata, P., Bid, H. K., Rivera, B. K., McCann, G. A., Tierney, B. J., ElNaggar, A. C., Bravo, V., Leone, G., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2433 · Cited by 95
Unphosphorylated STAT5A stabilizes heterochromatin and suppresses tumor growth
Hu, X., Dutta, P., Tsurumi, A., Li, J., Wang, J., Land, H., & Li, W. X. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221243110 · Cited by 95
STAT3 tyrosine phosphorylation influences survival in glioblastoma
Birner, P., Tumangelova-Yuzeir, K. D., Natchev, S., & Guentchev, M. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0195-8 · Cited by 91
Bain, B. J., & Ahmad, S. (2014) · British Journal of Haematology · doi:10.1111/bjh.12963 · Cited by 84
Marty, C., Saint‐Martin, C., Pecquet, C., Grosjean, S., Saliba, J., Mouton, C., Leroy, E., Harutyunyan, A. S., Abgrall, J.-F., Favier, R., et al. (2014) · Blood · doi:10.1182/blood-2013-05-504555 · Cited by 82
Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor
Becker, T. M., Boyd, S., Mijatov, B., Gowrishankar, K., Snoyman, S., Pupo, G. M., Scolyer, R. A., Mann, G. J., Kefford, R. F., Zhang, X. D., et al. (2013) · Oncogene · doi:10.1038/onc.2013.45 · Cited by 73
Pectasides, E., Egloff, A. M., Sasaki, C. T., Kountourakis, P., Burtness, B. A., Fountzilas, G., Dafni, U. G., Zaramboukas, T., Rampias, T. N., Rimm, D. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2658 · Cited by 69
Messina, J. L., Yu, H., Riker, A. I., Münster, P. N., Jove, R., & DAUD, A. I. (2008) · Cancer Control · doi:10.1177/107327480801500302 · Cited by 68
Dusa, A., Staerk, J., Elliott, J., Pecquet, C., Poirel, H. A., Johnston, J. A., & Constantinescu, S. N. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709302200 · Cited by 67
Grisouard, J., Shimizu, T., Duek, A., Kubovčáková, L., Hao-Shen, H., Dirnhofer, S., & Skoda, R. C. (2015) · Blood · doi:10.1182/blood-2014-08-594572 · Cited by 63
Kumar, J., Fraser, F. W., Riley, C. B., Ahmed, N., McCulloch, D. R., & Ward, A. C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.673 · Cited by 61
STAT5A/B Gene Locus Undergoes Amplification during Human Prostate Cancer Progression
Haddad, B. R., Gu, L., Mirtti, T. K., Dagvadorj, A., Vogiatzi, P., Hoang, D. T., Bajaj, R., Leiby, B. E., Ellsworth, E., Blackmon, S. M., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.02.044 · Cited by 52
Impact of isolated germline JAK2V617I mutation on human hematopoiesis
Mead, A. J., Chowdhury, O., Pecquet, C., Dusa, A., Woll, P. S., Atkinson, D., Burns, A., Score, J., Rugless, M. J., Clifford, R. M., et al. (2013) · Blood · doi:10.1182/blood-2012-05-430926 · Cited by 51
Mirtti, T. K., Leiby, B. E., Abdulghani, J., Aaltonen, E., Pavela, M., Mamtani, A., Alanen, K. A., Egevad, L., Granfors, T., Josefsson, A., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.06.001 · Cited by 44
Monnien, F., Zaki, H. M., Borg, C., Mougin, C., Bosset, J.-F., Mercier, M., Arbez‐Gindre, F., & Kantelip, B. M. (2010) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.076414 · Cited by 33
Sonnenblick, A., Uziely, B., Nechushtan, H., Kadouri, L., Galun, E., Axelrod, J. H., Katz, D., Daum, H., Hamburger, T., Mali, B., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2453-x · Cited by 32
Zhang, X., Blaskovich, M. A., Forinash, K. D., & Sebti, S. M. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.349 · Cited by 30
Confocal imaging studies cast doubt on nuclear localization of JAK2V617F
Girodon, F., Steinkamp, M. P., Cleyrat, C., Hermouet, S., & Wilson, B. S. (2011) · Blood · doi:10.1182/blood-2011-02-336479 · Cited by 15
Cited by
Macrophages in immunoregulation and therapeutics
Chen, S., Saeed, A. F. U. H., Liu, Q., Jiang, Q., Xu, H., Xiao, G. G., Rao, L., & Duo, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01452-1 · Cited by 2,229
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019) · Cancers · doi:10.3390/cancers11122002 · Cited by 714
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
The potential and controversy of targeting STAT family members in cancer
Verhoeven, Y., Tilborghs, S., Jacobs, J., De Waele, J., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X. B., Wouters, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.002 · Cited by 409
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Metadata
- Authors
- Thomas, S. J., Snowden, J. A., Zeidler, M. P., & Danson, S. J.
- Venue
- British Journal of Cancer
- Published
- 2015-07
- Volume
- 113
- Issue
- 3
- Pages
- 365-371
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1952507411
- Cited by
- 637
- References
- 58
- FWCI
- 17.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.